Evaluation of the Recombinant Zoster Vaccine Campaign Targeting Healthcare Professionals for Shingles Prevention Awareness in India

Shingles, or herpes zoster (HZ), results from the reactivation of the varicella-zoster virus, predominantly affecting older adults and immunocompromised individuals. A significant complication of HZ is post-herpetic neuralgia (PHN), which can cause chronic pain and significantly impact quality of life. The recombinant zoster vaccine (RZV) was developed to provide effective protection against shingles and related complications. This case study evaluates a public health campaign conducted on the Hidoc Dr. platform, targeting healthcare professionals (HCPs) across India to raise awareness about shingles prevention through vaccination. The six-month campaign employed a multi-channel approach to reach over 206,000 HCPs, generating 2.4 million impressions and 707 verified leads. Survey results indicated that 71.8% of HCPs acknowledged the vaccine's efficacy in reducing shingles risk in adults aged 50 and older. The campaign demonstrated a successful increase in awareness and engagement, highlighting the potential of similar initiatives to reduce shingles-related morbidity.